Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus warfarin in LVAD recipients
ACTRN12621000956808Phase 4Recruiting
- Sponsor
- St. Vincent Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in thrombosis and Bleeding comparing Apixaban plus antiplatelet agent with Warfarin standard of care (2 arms). Primary endpoint: Primary composite endpoint. Started Jan 2022; status: recruiting.
02
Drugs
apixabanwarfarin
03
Conditions
thrombosisBleeding
Beyond the preview
Go deeper on ACTRN12621000956808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000956808.